Patents by Inventor Harold E. Selick
Harold E. Selick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160296538Abstract: Cancer patients likely to respond to HAP treatment exhibit tumor tissues with high levels of hypoxia, which can be measured using PET imaging with [18F]-HX4.Type: ApplicationFiled: April 9, 2014Publication date: October 13, 2016Applicant: THRESHOLD PHARMACEUTICALS, INC.Inventors: Charles Hart, Harold E. Selick, Jessica Sun
-
Publication number: 20150272973Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.Type: ApplicationFiled: June 27, 2014Publication date: October 1, 2015Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
-
Patent number: 8765690Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.Type: GrantFiled: April 7, 2008Date of Patent: July 1, 2014Assignee: Threshold Pharmaceuticals, Inc.Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
-
Publication number: 20100104549Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.Type: ApplicationFiled: April 7, 2008Publication date: April 29, 2010Applicant: Threshold Pharmaceuticals, Inc.Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
-
Publication number: 20080160018Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 ? as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: November 20, 2006Publication date: July 3, 2008Applicant: PDL BioPharma, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: 7022500Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3? as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: November 22, 2000Date of Patent: April 4, 2006Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Harold E. Selick
-
Publication number: 20040058414Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: May 30, 2003Publication date: March 25, 2004Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20040049014Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: March 11, 2004Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030229208Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: December 11, 2003Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030073069Abstract: Otherwise efficacious drugs having an ADMET/PK (absorption, distribution, metabolism, elimination, toxicity, i.e., pharmacokinetic) problem are redesigned or “rescued” by applying computational techniques that identify related chemical structures that preserve the initial drug's effectiveness but improve its ADMET/PK properties. The otherwise efficacious drug may be subjected to a suite of computational tools that identify sites responsible for problematic ADMET/PK properties and/or identify related compounds that have improved ADMET/PK properties.Type: ApplicationFiled: October 15, 2001Publication date: April 17, 2003Inventors: Harold E. Selick, Kenneth R. Korzekwa, Katrin Mackarehtschian
-
Patent number: 6180370Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: January 30, 2001Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Harold E. Selick
-
Patent number: 6168914Abstract: The invention provides a system and method for synthesizing chemicals onto supports in a parallel manner to produce a combinatorial collection of compounds. The system includes a plurality of middle plates, with each middle plate defining a plurality of reaction zones arranged in a two dimensional array. The reaction zones are adapted to receive a solid support, such as a sheet of membrane, and the middle plates are stackable on each other to form a three dimensional array of reaction zones. The system also includes a pair of end plates, where the middle plates are located between the end plates, and where the end plates include an array of fluid guides corresponding to the array of reaction zones, to allow for selective routing of reagents through the reaction zones.Type: GrantFiled: December 18, 1998Date of Patent: January 2, 2001Assignee: Glaxo Wellcome Inc.Inventors: David A. Campbell, Valery V. Antonenko, Harold E. Selick, Robert M. Gavin, Satoru Ida, Arthur H. Muir
-
Patent number: 6083682Abstract: The invention provides a system and method for synthesizing chemicals onto supports in a parallel manner to produce a combinatorial collection of compounds. The system includes a plurality of middle plates, with each middle plate defining a plurality of reaction zones arranged in a two dimensional array. The reaction zones are adapted to receive a solid support, such as a sheet of membrane, and the middle plates are stackable on each other to form a three dimensional array of reaction zones. The system also includes a pair of end plates, where the middle plates are located between the end plates, and where the end plates include an array of fluid guides corresponding to the array of reaction zones, to allow for selective routing of reagents through the reaction zones.Type: GrantFiled: December 19, 1997Date of Patent: July 4, 2000Assignee: Glaxo Group LimitedInventors: David A. Campbell, Valery V. Antonenko, Harold E. Selick
-
Patent number: 6043027Abstract: The invention provides exemplary testing devices, systems, and methods for evaluating the permeation of various chemicals through different types of cells. In one exemplary embodiment, a testing device is provided which comprises a base member and a top member having a plurality of wells which are aligned when the top member is secured to the base member. A membrane sheet which includes at least one layer of cells grown on the sheet is placed between the base member and the top member prior to assembly. Test samples are placed into the wells in the top member and samples are removed from the top and bottom wells at a later time and tested to determine the amount of test sample which permeated through the cells.Type: GrantFiled: October 26, 1998Date of Patent: March 28, 2000Assignee: Glaxo Wellcome Inc.Inventors: Harold E. Selick, Gregory A. Smith, John W. Tolan
-
Patent number: 5962250Abstract: The invention provides exemplary testing devices, systems, and methods for evaluating the permeation of various chemicals through different types of cells. In one exemplary embodiment, a testing device is provided which comprises a plate defining at least one well having an open top end. At least one membrane is insertable into the well in a generally vertical orientation to divide the well into separate chambers. The membrane is removable from the well to allow the cells to be grown on the membrane before insertion into the well.Type: GrantFiled: October 28, 1997Date of Patent: October 5, 1999Assignee: Glaxo Group LimitedInventors: Robert M. Gavin, Harold E. Selick, Gregory A. Smith
-
Patent number: 5814603Abstract: PTH analogs comprising an amino acid sequence that is: SVSEIQLLHNX.sub.1 X.sub.2 X.sub.3 HX.sub.4 X.sub.3 X.sub.3 X.sub.3 X.sub.5 RVX.sub.5 WLR X.sub.4 X.sub.4 LX.sub.3 X.sub.3 VX.sub.1 X.sub.3 X.sub.3 X (SEQ ID NO:10) wherein X.sub.1 is a neutral or positively charged amino acid, X.sub.2 is a neutral amino acid, X.sub.3 is a neutral, positively charged, or negatively charged amino acid, X.sub.4 is a positively charged amino acid, X.sub.5 is a positively charged or negatively charged amino acid, and X is selected from the group consisting of Hol, Ho, a homoserine amide, or the sequence of amino acids comprising residues 35-84 of PTH, have enhanced activity and increased serum half-life as compared with human PTH. The PTH analogs can be produced as fusion proteins in high yields in E. coli host cells; the fusion proteins can be subsequently cleaved to produce the PTH analog.Type: GrantFiled: October 25, 1993Date of Patent: September 29, 1998Assignee: Affymax Technologies N.V.Inventors: Kevin R. Oldenburg, Harold E. Selick
-
Patent number: 5693761Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: December 2, 1997Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, William P. Schneider, Harold E. Selick
-
Patent number: 5693762Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: December 2, 1997Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: 5607691Abstract: The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.Type: GrantFiled: May 24, 1995Date of Patent: March 4, 1997Assignee: Affymax Technologies N.V.Inventors: Ron L. Hale, Amy Lu, Dennis Solas, Harold E. Selick, Kevin R. Oldenburg, Alejandro C. Zaffaroni
-
Patent number: 5585089Abstract: Novel methods for producing, and compositions of humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: December 17, 1996Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Harold E. Selick